AIMS/HYPOTHESIS: Acute clamped hyperglycaemia activates the renin-angiotensin-aldosterone system (RAAS) and increases the urinary excretion of inflammatory cytokines/chemokines in patients with uncomplicated type 1 diabetes mellitus. Our objective was to determine whether blockade of the RAAS would blunt the effect of acute hyperglycaemia on urinary cytokine/chemokine excretion, thereby giving insights into potentially protective effects of these agents prior to the onset of clinical nephropathy. METHODS: Blood pressure, renal haemodynamic function (inulin and para-aminohippurate clearances) and urinary cytokines/chemokines were measured after 6 h of clamped euglycaemia (4-6 mmol/l) and hyperglycaemia (9-11 mmol/l) on two consecutive days in patients with type 1 diabetes mellitus (n = 27) without overt nephropathy. Measurements were repeated after treatment with aliskiren (300 mg daily) for 30 days. RESULTS: Before aliskiren, clamped hyperglycaemia increased filtration fraction (from 0.188 ± 0.007 to 0.206 ± 0.007, p = 0.003) and urinary fibroblast growth factor-2 (FGF2), IFN-α2 and macrophage-derived chemokine (MDC) (p < 0.005). After aliskiren, the filtration fraction response to hyperglycaemia was abolished, resulting in a lower filtration fraction after aliskiren under clamped hyperglycaemic conditions (p = 0.004), and none of the biomarkers increased in response to hyperglycaemia. Aliskiren therapy also reduced levels of urinary eotaxin, FGF2, IFN-α2, IL-2 and MDC during clamped hyperglycaemia (p < 0.005). CONCLUSIONS/ INTERPRETATION: The increased urinary excretion of inflammatory cytokines/chemokines in response to acute hyperglycaemia is blunted by RAAS blockade in humans with uncomplicated type 1 diabetes mellitus.
AIMS/HYPOTHESIS: Acute clamped hyperglycaemia activates the renin-angiotensin-aldosterone system (RAAS) and increases the urinary excretion of inflammatory cytokines/chemokines in patients with uncomplicated type 1 diabetes mellitus. Our objective was to determine whether blockade of the RAAS would blunt the effect of acute hyperglycaemia on urinary cytokine/chemokine excretion, thereby giving insights into potentially protective effects of these agents prior to the onset of clinical nephropathy. METHODS: Blood pressure, renal haemodynamic function (inulin and para-aminohippurate clearances) and urinary cytokines/chemokines were measured after 6 h of clamped euglycaemia (4-6 mmol/l) and hyperglycaemia (9-11 mmol/l) on two consecutive days in patients with type 1 diabetes mellitus (n = 27) without overt nephropathy. Measurements were repeated after treatment with aliskiren (300 mg daily) for 30 days. RESULTS: Before aliskiren, clamped hyperglycaemia increased filtration fraction (from 0.188 ± 0.007 to 0.206 ± 0.007, p = 0.003) and urinary fibroblast growth factor-2 (FGF2), IFN-α2 and macrophage-derived chemokine (MDC) (p < 0.005). After aliskiren, the filtration fraction response to hyperglycaemia was abolished, resulting in a lower filtration fraction after aliskiren under clamped hyperglycaemic conditions (p = 0.004), and none of the biomarkers increased in response to hyperglycaemia. Aliskiren therapy also reduced levels of urinary eotaxin, FGF2, IFN-α2, IL-2 and MDC during clamped hyperglycaemia (p < 0.005). CONCLUSIONS/ INTERPRETATION: The increased urinary excretion of inflammatory cytokines/chemokines in response to acute hyperglycaemia is blunted by RAAS blockade in humans with uncomplicated type 1 diabetes mellitus.
Authors: Maria-Dolores Sanchez-Niño; Milica Bozic; Elizabeth Córdoba-Lanús; Petya Valcheva; Olga Gracia; Merce Ibarz; Elvira Fernandez; Juan F Navarro-Gonzalez; Alberto Ortiz; Jose Manuel Valdivielso Journal: Am J Physiol Renal Physiol Date: 2011-12-14
Authors: D Z I Cherney; J W Scholey; D Daneman; D B Dunger; R N Dalton; R Moineddin; F H Mahmud; R Dekker; Y Elia; E Sochett; H N Reich Journal: Diabet Med Date: 2012-10 Impact factor: 4.359
Authors: David Z I Cherney; James W Scholey; Shan Jiang; Ronnie Har; Vesta Lai; Etienne B Sochett; Heather N Reich Journal: Diabetes Care Date: 2012-07-26 Impact factor: 19.112
Authors: Julie A Lovshin; Geneviève Boulet; Yuliya Lytvyn; Leif E Lovblom; Petter Bjornstad; Mohammed A Farooqi; Vesta Lai; Leslie Cham; Josephine Tse; Andrej Orszag; Daniel Scarr; Alanna Weisman; Hillary A Keenan; Michael H Brent; Narinder Paul; Vera Bril; Bruce A Perkins; David Zi Cherney Journal: JCI Insight Date: 2018-01-11
Authors: Yuliya Lytvyn; Petter Bjornstad; Julie A Lovshin; Genevieve Boulet; Mohammed A Farooqi; Vesta Lai; Josephine Tse; Leslie Cham; Leif E Lovblom; Alanna Weisman; Hillary A Keenan; Michael H Brent; Narinder Paul; Vera Bril; Andrew Advani; Etienne Sochett; Bruce A Perkins; David Z I Cherney Journal: Am J Kidney Dis Date: 2019-02-22 Impact factor: 8.860
Authors: Petter Bjornstad; R Brett McQueen; Janet K Snell-Bergeon; David Cherney; Laura Pyle; Bruce Perkins; Marian Rewers; David M Maahs Journal: PLoS One Date: 2014-04-29 Impact factor: 3.240
Authors: Hongyan Liu; Vikas S Sridhar; Leif Erik Lovblom; Yuliya Lytvyn; Dylan Burger; Kevin Burns; Davor Brinc; Patrick R Lawler; David Z I Cherney Journal: Kidney Int Rep Date: 2021-06-05
Authors: Adeera Levin; Evan Adams; Brendan J Barrett; Heather Beanlands; Kevin D Burns; Helen Hoi-Lun Chiu; Kate Chong; Allison Dart; Jack Ferera; Nicolas Fernandez; Elisabeth Fowler; Amit X Garg; Richard Gilbert; Heather Harris; Rebecca Harvey; Brenda Hemmelgarn; Matthew James; Jeffrey Johnson; Joanne Kappel; Paul Komenda; Michael McCormick; Christopher McIntyre; Farid Mahmud; York Pei; Graham Pollock; Heather Reich; Norman D Rosenblum; James Scholey; Etienne Sochett; Mila Tang; Navdeep Tangri; Marcello Tonelli; Catherine Turner; Michael Walsh; Cathy Woods; Braden Manns Journal: Can J Kidney Health Dis Date: 2018-01-17